A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies
Internal Medicine Journal · 2025
DOI: 10.1111/imj.16647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von P Joy Ho und 1 weiteren Autor:innen. Beteiligte Einrichtung: Royal Prince Alfred Hospital, Institute of Haematology, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Immunotherapy, Adoptive, Multiple Myeloma, Receptors, Chimeric Antigen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
T‐cell re‐directional therapies, including chimeric antigen receptor (CAR)‐T cell and bispecific antibodies (BsA), have transformed the treatment landscape to benefit patients with multiple myeloma. A number of these novel therapies has been approved internationally, with CAR‐T therapy recently approved in Australia. In this clinical perspective, we describe the development of CAR‐T and BsA therapies, highlighting the clinical benefits and risks, together with the significant costs and infrastructure support required for the provision of these therapies to myeloma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Royal Prince Alfred Hospital, Institute of Haematology, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: P Joy Ho
Zitieren
APA
Ho, P. J., & Li, E. W. (2025). A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies. Internal Medicine Journal. https://doi.org/10.1111/imj.16647
Vancouver
Ho PJ, Li EW. A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies. Internal Medicine Journal. 2025. doi:10.1111/imj.16647
BibTeX
@article{Ho2025,
author = {Ho, P Joy and Li, Eric W},
title = {A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.16647}
}
EUVIMED